RecruitingPhase 2NCT07610369

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

Sponsor

Yale University

Enrollment

40 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

Depression Parkinson's Disease (PD)

Summary

The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

Eligibility

Min Age: 40 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Psilocybin (drug) and Psilocybin (drug) for people with depression and parkinson's disease (pd). The study is currently recruiting participants at 1 location. People eligible for this study include aged 40 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPsilocybin (drug)

Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring

DRUGPsilocybin (drug)

Single dose of psilocybin ranging from low ("microdose") to high delivered orally with psychological support and monitoring

Locations(1)

Yale University

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07610369

Related Trials

Internet Based Psychological Support

NCT027260611 location

Adaptive Coping Skills Training to Improve Psychological Distress Among Cardiorespiratory Failure Survivors

NCT065382461 location